Objective To provide evidence-based recommendations regarding the diagnosis and
management of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis …

Given the increasing prevalence of diabetes and obesity worldwide, the deleterious effects
of non-alcoholic fatty liver disease (NAFLD) are becoming a growing challenge for public …

Abbreviations: AASLD, American Association for the Study of Liver Diseases; AI, artificial
intelligence; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AUROC …

Chronic liver injury leads to liver inflammation and fibrosis, through which activated
myofibroblasts in the liver secrete extracellular matrix proteins that generate the fibrous scar …

This patient guideline is intended for all patients at risk of or living with non-alcoholic fatty
liver disease (NAFLD). NAFLD is the most frequent chronic liver disease worldwide and …

Glucagon like peptide-1 (GLP-1) is an incretin secretory molecule. GLP-1 receptor agonists
(GLP-1RAs) are widely used in the treatment of type 2 diabetes (T2DM) due to their …

Objective The development of these updated clinical practice guidelines (CPG) was
commissioned by the American Association of Clinical Endocrinologists, The Obesity …

Importance Nonalcoholic steatohepatitis (NASH) is the inflammatory subtype of nonalcoholic
fatty liver disease (NAFLD) and is associated with disease progression, development of …

Background Non-alcoholic fatty liver disease (NAFLD) is rapidly becoming a global health
problem. Cardiovascular diseases (CVD) are the most common cause of mortality in NAFLD …

Background and Aims Studies are needed to determine the long-term effects of bariatric
surgery for patients with nonalcoholic steatohepatitis (NASH). We evaluated sequential liver …